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Cytophagic histiocytic panniculitis is a rare disease, associated with either nonmalignant conditions or
subcutaneous panniculitis-like T-cell lymphoma, and often also associated with hemophagocytic lymphohistiocytosis
(HLH). We report the case of a 11-year-old boy with a history of secondary HLH who, after a local trauma,
developed a painful, indurated plaque over the right thigh associated with relapsing HLH. Histopathologic findings from
skin biopsy specimens revealed significant lobular panniculitis with benign histiocytes showing hemophagocytosis.
High-dose intravenous methylprednisolone and cyclosporine A treatment was highly effective. A genetic study after a
new, relapsing episode of HLH revealed an heterozygous missense mutation on STX 11 gene inherited from the mother.
Keywords: Panniculitis, Histiocytes, HemophagocytosisBackground
Cytophagic histiocytic panniculitis (CHP) is a rare disease,
first described in 1980, characterized by infiltration of sub-
cutaneous adipose tissue by benign-appearing T lympho-
cytes and phagocytic histiocytes (“bean bag cells”) [1]. CHP
may be an isolated skin disease or associated with non-
malignant conditions, such as infections, as well as malig-
nancies, including subcutaneous panniculitis-like T-cell
lymphoma (SPTL), a rare form of non-Hodgkin lymphoma
infiltrating into subcutaneous adipose tissue [2]. Subcutane-
ous panniculitis has been reported in a small number of pa-
tients with hemophagocytic lymphohistiocytosis (HLH), a
life threatening condition characterized by uncontrolled ac-
tivation and proliferation of T-cells resulting in hypercytoki-
nemia, proliferation of histiocytes and hemophagocytosis
[3,4]. The familial form of HLH (FHL) is a genetically het-
erogeneous disorder caused by mutations in genes involved
in the granule-dependent exocytosis pathway. Patients with
FHL are unable to cope with common pathogens; thus* Correspondence: debenedictis@ospedaliriuniti.marche.it
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unless otherwise stated.upon infection with widely diffused agents as cytomegalo-
virus and Epstein Barr virus, but also less common as leish-
mania, they develop clinical symptoms and findings of
HLH [5]. In order to facilitate the diagnosis of HLH, a set
of diagnostic criteria have been developed by the Histiocyte
Society [6].
About 40 cases of CHP have been reported so far, mostly
in adults [2]. Patients with CHP may have three different
clinical courses, mainly depending on isolated presentation
or association with HLH. Some patients rapidly progress
and often die within one year, due to sepsis, coagulation
disorders and multi-organ failure. Others have recurrent
bouts of reactivation and may survive for years. Other pa-
tients respond well to treatment and may have a normal
life [7,8].
We report a severe HLH-associated CHP successfully
treated with systemic corticosteroids and cyclosporin A in
a child with relapsing HLH and persistent ANA positivity
at follow-up.
Case presentation
A previously healthy 11-year-old boy was admitted to our
department with persistent fever and increasing dyspnea.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Hyperpigmented, indurated plaque with hyperkeratosic
central area over the right thigh.
Figure 2 Skin biopsy specimen. a) Hematoxylin-eosin stain (4x)
showing subcutaneous infiltrate, mainly constituted of mononuclear
cells; b) Immunohistochemical stain (20x) showing infiltrating
histiocytes expressing CD68.
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had high-grade fever and moderate respiratory distress.
Chest examination revealed dullness on percussion and
absent breath sound on the right hemithorax. Laboratory
tests showed pancytopenia, impaired liver function, raised
triglycerides and ferritin levels and low albumin value,
without coagulopathy. Anti-nuclear antibodies (ANA)
were positive 1:128 with homogeneous pattern. Autoanti-
body profile (anti-endonuclear, -cardiolipin, -beta2 glyco-
protein I, -thyroid, -neutrophil cytoplasm, -mitochondrial
and -smooth muscle antibodies) was negative. Blood and
urine culture were negative. Virological tests revealed
prior/remote Epstein-Barr virus (EBV) infection and nega-
tive serology for hepatitis viruses A, B, C, or cytomegalo-
virus. Chest x-ray showed homogeneous opacity of the
right hemithorax. Ultrasound of the chest and abdomen
revealed massive pleural effusion, and pericholecystic,
perisplenic and perihepatic fluid collection. A chest tube
was positioned and a total of 270 ml of cloudy pleural
fluid was drained: cytology and biochemical analysis re-
vealed leukocytes 490/mcL (80% lymphocytes), glucose
93 mg/dL, proteins 4,3 gr/dL, lactate dehydrogenase
3948 IU/L; no bacteria were found at the Gram and acid
fast bacilli stain; the culture was negative. Bone marrow
aspirate showed an increased number of histiocytes
phagocyting red cells and platelets. The number of T, B
and NK cells, and granzyme B concentration were
within normal ranges. No mutations in PRF1, UNC13D,
STXBP2, the genes most frequently associated with familial
HLH, were found. HLH secondary to undetermined auto-
immune disorder was diagnosed, and treatment with oral
dexamethasone (initially 10 mg/m2 for 2 weeks followed by
5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2
for one week, and one week of tapering), cyclosporin
(6 mg/kg daily) and intravenous etoposide (150 mg/m2
twice weekly for 2 weeks and then weekly) was adminis-
tered for 8 weeks. All symptoms gradually resolved and the
patient was maintained on a regular follow-up.
One year later, the child presented with spiking fever
and painful swelling of the right thigh which had gradually
developed some days after a local trauma. Physical exam-
ination revealed a warm, painful, indurated plaque (10x12
cm diameter) over the right thigh. Liver and spleen were
mildly enlarged. Routine laboratory tests were non-
contributory. ANA were positive 1:1024 with granular pat-
tern. Over a few days, the lesion progressively enlarged
and a brownish, hyperpigmented, hyperkeratosic central
area appeared (Figure 1). Laboratory tests and bone mar-
row aspirate were consistent with reactivation of HLH.
Skin biopsy revealed a mixed septal and lobular inflamma-
tory infiltrate of benign-appearing histiocytes, plasma cells
and lymphocytes, and diffuse fat necrosis (Figure 2a); ex-
tensive hemophagocytosis by histiocytic cells was also evi-
dent. At the immuno-histochemical staining, nearly all the
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toxic T-cell: CD2, CD3, CD5, CD8, but not CD4; CD7 ex-
pression was weak to negative; most histiocytes expressed
CD68 (Figure 2b). Polymerase chain reaction analysis of
the T-cell receptor-gamma chain gene rearrangement
confirmed the absence of clonality. Testing for EBV
virus by in situ hybridization was negative. A diagnosis
of HLH-associated CHP was made. High-dose pulse of
intravenous methylprednisolone (30 mg/kg/day for 3 days)
was started, followed by a combination of dexamethasone
(0.25 mg/kg daily) and cyclosporin A (6 mg/kg daily). A
dramatic clinical improvement was observed. Dexametha-
sone was discontinued after 8 weeks, while cyclosporin A
was maintained for 12 months.
Six months after discontinuation of cyclosporine A ther-
apy, the patient was admitted for reactivation of HLH
(Table 1). Thus, a more extensive genetic study for familial
HLH was performed. Mutation analysis revealed heterozy-
gous missense mutation (c.991G >A p.V267M) in the
STX11 gene. In silico analysis performed using the web
query tools (Pmut, Polyphen, SIFT) confirmed that this
mutation is not tolerated. Combined treatment with ste-
roids (high-dose pulse of intravenous methylprednisolone
30 mg/kg/day for 3 days, followed by dexamethasone
0.10 mg/kg daily) and cyclosporine A (5 mg/kg daily) was
reinstituted for 6 weeks and 12 months, respectively. Clin-
ical and laboratory remission was sustained at 6 month
follow-up. Over the years, ANA title remained persistently
positive 1:256 to 1:1024 with granular pattern.
Conclusions
Our case is worthy of description for several reasons. First,
there is no mention in the literature of autoimmune in-
volvement in patients with CHP. ANA were positive at theTable 1 Clinical features and laboratory findings at first admi
1st admission
Clinical features Spiking fever
Respiratory distress
Absent breath sound on right hemithora
Laboratory findings
Red blood cells (x106) 4.250








Bone marrow Phagocyting histiocytespresentation of HLH and their values remained persist-
ently high over the years. The meaning of ANA positivity
in the picture of systemic disease remains intriguing. Ravelli
et al. [9] suggested that ANA positivity is the hallmark of a
specific subset of patients with juvenile idiopathic arthritis
which should be classified separately for their different
prognosis [10]. Whether persistent ANApositivity in our
patient may represent a different setting of the immune sys-
tem cannot be defined at present. Furthermore, a local
trauma was revealed some days before panniculitis was evi-
dent. To our knowledge, this finding has not been reported
in CHP and trauma might act as precipitating factor.
The spectrum of mutations involved in FHL has ex-
panded since the original report of perforin defect in 1999,
with mutations identified in the UNC13D (FHL3), STX11
(FHL4) and STXBP2 (FHL5) genes [11]. While original re-
ports of FHL4 were restricted to families of Turkish/Kurd-
ish origin, patients of different origins have been recently
identified with defect in STX11 [11,12]. The relevance of
cooperation between the syntaxins and other proteins in-
volved in the degranulation machinery is being progres-
sively elucidated [13]. Recent studies in patients with FHL
suggested that monoallelic mutation in FHL-related genes
may behave as predisposing factor for several human disor-
ders [14-16]. The working hypothesis is that partial impair-
ment of the cellular cytotoxicity machinery may predispose,
or contribute, to several disorders in which the immune
system plays a significant role [11,12]. Our patient bears a
monoallelic, novel STX11 mutation, which was predicted
to be pathogenic by in silico analysis.
Once CHP is suspected, the diagnosis relies mainly on
histopathology findings. In such context, discriminating be-
tween CHP and SPTL is therapeutically important because
nonmalignant CHP often improves under pulses of high-ssion and at relapses
1st relapse 2nd relapse
Spiking fever Fever
Swelling of the right tight Cough









Granular pattern Granular pattern
Phagocyting histiocytes
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[17], whereas most cases of SPTL may be best treated with
more aggressive therapy. Marzano et al. [18] suggested
that these conditions might span a clinical-pathological
spectrum in which there is a natural progression from
CHP to SPTL. Since the distinction of CHP from SPTL
is difficult and CHP might be a precursor of SPTL [19],
some authors proposed to use the term “panniculitis-like
subcutaneous lymphoma with cytophagocytosis” instead
of CHP, even when T-cell clonality was not documented
[20]. This approach would have a beneficial effect on treat-
ment planning towards oncological rather than anti-
inflammatory therapy. Bader-Meunier et al. [21] recently
emphasized that HLH-associated CHP may be diagnosed
despite monoclonal T-cell proliferation that mimics SPTL
and is best treated by prednisone and cyclosporine A, at
least in children. It has been suggested that this florid
clonal T-cell proliferation is reactive, probably driven by a
strong immune reaction against EBV infection [22]. Fur-
thermore, Huppmann et al. [23] confirmed that molecular
studies are diagnostically helpful but not specific, since the
absence of clonality does not rule out the diagnosis of
SPTL.
The diagnosis of CHP is challenging, but it was sup-
ported by several data in our case. Although many histo-
pathology findings are common to both CHP and SPTL,
rimming of the fat vacuoles by atypical lymphoid cells is a
useful diagnostic feature for SPTL [24]. Furthermore, the
development of HLH is extremely rare, has an aggressive
course and is typically associated with a poor outcome in
children with SPTL [25]. In our patient, the rimming pat-
tern was absent in the skin infiltrate and the outcome of
HLH was favourable.
Another entity within the differential diagnosis
spectrum of lobular panniculitis is lupus erythematosus
panniculitis (LEP) [26], a rare variant of lupus erythe-
matosus which can present as an isolated phenomenon
and is most commonly localized to upper arm. The
presence of HLH in LEP, has been rarely described [27].
Male gender, involvement of the thigh, good response
to therapy, lack of relapse after treatment discontinu-
ation, and absence of characteristic histopathology
findings of lupus erythematosus supported the diagno-
sis of CHP.
The remission of the symptoms of CHP and HLH
under the association of high-dose intravenous meth-
ylprednisolone and cyclosporine A in our patient sup-
ports that this combination is the treatment of choice
for nonmalignant CHP associated with HLH. Cytotoxic
chemotherapy should be considered for relapsing/refractory
disease or more severe forms [28]. High-dose chemother-
apy followed by autologous peripheral blood stem cell
transplantation may be necessary for the treatment of par-
ticularly aggressive CHP [29].The small number of reported patients with HLH-
associated CHP does not permit to hypothesize any fac-
tor that may predict the clinical course or guide the op-
timal treatment. Searching for biological features such
as underlying genetic mutations may help to better
understand the variability of the clinical course and the
response to treatment. Prompt diagnosis of CHP and
HLH, close cooperation between rheumatologists, he-
matologists, dermatologists and pathologists, and con-
tinued follow up remain an imperative matter that can
make the difference between life and death.
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